Testimony
Before the Committee
on Environment and Public Works
United
States Senate
Bioterrorism:
The Role of CDC and ATSDR in Remediating Contaminated
Buildings
Statement of
Patrick
J. Meehan, M.D.
Director,
Division
of Emergency and Environmental Health Services,
National
Center for Environmental Health,
Centers
for Disease Control and Prevention
Department
of Health and Human Services
For Release on Delivery
Expected at 9:30 am
on
Tuesday, December 4, 2001
Good morning, Mr. Chairman and
Members of the Subcommittee. I am Dr. Patrick Meehan,
Director, Division of Emergency and Environmental Health
Services, Centers for Disease Control and Prevention (CDC),
Department of Health and Human Services (HHS). Thank you
for the invitation to discuss CDC's and HHS's Agency for
Toxic Substances and Disease Registry's (ATSDR) role in
supporting the Environmental Protection Agency (EPA) in
remediating anthrax-contaminated workplaces. My division
includes CDC's National Pharmaceutical Stockpile (NPS)
as well as coordination of emergency preparedness and
response activities under the Federal Response Plan.
Today, I will update you on the
intentional release of anthrax and the number of exposed
and affected persons, as well as summarize CDC and ATSDR's
efforts to identify exposure, prevent anthrax disease,
and monitor the health of those known to be exposed. I
will also discuss CDC and ATSDR's collaboration with the
EPA to assist in remediating contaminated buildings and
protecting the health of workers in those buildings.
I would like to begin by emphasizing
the importance of remediating all anthrax-contaminated
worksites. CDC and ATSDR have worked, and will continue
to work diligently along with EPA and our federal, state,
and local public health partners to help achieve this
goal. Every worker in the United States deserves a safe
and healthy workplace. In the past two months, terrorists
have used anthrax spores to disrupt, displace, and even
infect American workers. One phase of the fight against
terrorism is to remediate contaminated workplaces and
protect the health and safety of American workers who
need to return to their jobs. We must also protect those
workers whose job it is to investigate and clean these
work places. These are the people who have been on the
front lines of this battle, and they deserve our help
and support.
As you are aware, many facilities
in communities around the country have received anthrax
threat letters. Most were received as empty envelopes;
some have contained powdery substances. However, in some
cases, actual anthrax exposures have occurred. These cases
have been identified in Florida, New Jersey, New York,
Washington, DC, and Connecticut. This is the first bioterrorism-related
anthrax attack in the United States, and the public health
ramifications of this attack continue to evolve. In collaboration
with state and local health and law enforcement officials,
CDC, ATSDR, and the Federal Bureau of Investigation (FBI)
are continuing to conduct health investigations related
to anthrax exposures. During this heightened surveillance,
cases of illness that may reasonably resemble symptoms
of anthrax have been thoroughly reviewed. The public health
and medical communities continue to be on a heightened
level of disease monitoring to ensure that any potential
exposure is recognized and that appropriate medical evaluations
are given. This is an example of the disease monitoring
system in action, and that system is working.
Public Health Leadership
The Department of Health and
Human Services' (DHHS) anti-bioterrorism efforts are focused
on improving the nation's public health surveillance network
to quickly detect and identify the biological agent that
has been released; strengthening the capacities for medical
response, especially at the local level; expanding the
stockpile of pharmaceuticals for use when needed; expanding
research on disease agents that might be released, rapid
methods for identifying biological agents, and improved
treatments and vaccines; and regulating the shipment of
hazardous biological agents or toxins.
As the Nation's disease prevention
and control agency, it is CDC's responsibility on behalf
of DHHS to provide national leadership in the public health
and medical communities in a concerted effort to detect,
diagnose, respond to, and prevent illnesses, including
those that occur as a result of a deliberate release of
biological agents. This task is an integral part of CDC's
overall mission to monitor and protect the health of the
U.S. population.
Remediation Support Activities
Since the intentional release
of anthrax spores, one of the areas on which CDC and ATSDR
have focused is the identification and cleanup of contaminated
facilities. We have refined methods for environmental
sampling to assess whether anthrax contamination had occurred;
in buildings that has meant sampling of air and surfaces.
CDC and ATSDR have issued recommendations on how to conduct
environmental sampling and how laboratories should analyze
those samples. We also recommended environmental sampling
strategies to characterize the extent of exposure and
to guide cleanup. We issued recommendations to protect
first responders, investigators, and cleanup personnel.
As buildings were identified as contaminated, we provided
technical input to EPA and others tasked with cleanup
to determine where remediation was necessary. These recommendations
have been widely disseminated to federal, state and local
health and environmental agencies, and are available at
CDC's bioterrorism website (www.bt.cdc.gov).
EPA has devised strategies for
remediation and has gained much experience through its
activities to date. Disease experts at CDC are developing
strategies to prevent the spread of disease during and
after bioterrorist attacks. Although there are some data
on chemical disinfectants in the scientific literature,
there are no historical data that indicate the best way
to eliminate spores from an office building, or to disinfect
a sorting machine. The ability of a disinfectant to kill
an anthrax spore is dependent upon time of contact and
concentration and is mitigated by the amount and composition
of material through which it must penetrate to get to
the spore. For many of the clean-up methods being used
to kill anthrax spores, we will not know their effectiveness
until we go through the process. EPA understands this
and has sought help from a variety of sources, including
CDC and ATSDR, to ensure that the appropriate indicators
are used and that post-sampling strategies are adequate.
With regard to the effectiveness
of cleaning, even our most exhaustive sampling strategies
will not identify every spore. It is unlikely that any
cleaning strategy will kill every spore. However, the
EPA should be able to clean and re-test to the point where
we all are comfortable that spores have been killed or
removed from surfaces where human contact is likely to
occur. A range of sampling methods and strategies should
be used to ensure the safety of building occupants.
In heavily contaminated areas,
such as Senator Daschle's suite and the Brentwood postal
facility, fumigation is being proposed as the method of
clean-up. The use of fumigants is a potential hazard for
clean-up workers, those in areas adjacent to the buildings,
and those that must re-occupy the building. A fumigant
that is effective at killing spores is, of necessity,
a highly toxic agent. The protection of workers during
the fumigation process is a matter of good industrial
hygiene. EPA, CDC, and ATSDR are working together to ensure
remediation workers are protected during the fumigation
processes. EPA works with local public health agencies
to ensure that people in the area but outside of the building
being fumigated are notified and kept at a safe distance.
With regard to the safety of
those who will re-occupy the building, it is important
to determine both that the area is clear of the fumigant
and that there is no health risk. Again, CDC, ATSDR, and
the Occupational Safety and Health Administration (OSHA)
have developed exposure limits for fumigants, and detection
methods are available to determine when any residual fumigant
is well below established limits. After buildings are
cleaned and post-cleaning environmental sampling has been
conducted, CDC and ATSDR are committed to providing technical
input to the incident command and other experts to determine
whether the building is ready for re-occupancy.
Challenges
CDC has been addressing issues
of detection, epidemiologic investigation, diagnostics,
and enhanced infrastructure and communications as part
of its overall bioterrorism preparedness strategies. Based
on federal, state, and local response in the weeks following
the events of September 11 and on recent training experiences,
CDC has learned valuable lessons and identified gaps that
exist in bioterrorism preparedness and response at federal,
state, and local levels. CDC will continue to work with
partners to address challenges such as improving coordination
among other federal agencies during a response and understanding
the necessary relationship needed between conducting a
criminal investigation versus an epidemiologic case investigation.
These issues, as well as overall preparedness planning
at federal, state, and local levels, require additional
action to ensure that the nation is fully prepared to
respond to acts of biological and chemical terrorism.
Conclusion
In conclusion, CDC and ATSDR
are committed to working with other federal agencies and
partners as well as state and local public health departments
to ensure the health and medical care of our citizens.
We are committed to continuing our partnership with EPA
to ensure that the best public health information is coupled
with the best ideas for how to remediate contaminated
facilities. We need to improve sampling methods and equipment.
We must learn from this experience and continue to assist
the EPA in determining the best ways to remediate different
types of workplace environments having different amounts
of anthrax contamination.
Thank you very much for your
attention. I will be happy to answer any questions you
may have.
HHS Home (www.hhs.gov) |
Topics (www.hhs.gov/SiteMap.html) |
What's New (www.hhs.gov/about/index.html#topiclist) |
For Kids (www.hhs.gov/kids/) |
FAQs (answers.hhs.gov) |
Site Info (www.hhs.gov/SiteMap.html) |
Disclaimers (www.hhs.gov/Disclaimer.html) |
Privacy Notice (www.hhs.gov/Privacy.html) |
FOIA (www.hhs.gov/foia/) |
Accessibility (www.hhs.gov/Accessibility.html) |
Contact Us (www.hhs.gov/ContactUs.html)
Last
revised: December 4, 2001